Predictive molecular genetics in the diagnosis and treatment of families with multiple endocrine neoplasia type 2;Pradiktive genetische untersuchungen: Individualisierung von diagnostik und therapie bei familien mit multipler endokriner neoplasie typ II

Deutsche Medizinische Wochenschrift

Volumn 125, Issue 3, 2000, Pages 37-44

  Engelbach, M ^a   Kunt, T ^a   Kann, P ^a   Manfras, B ^b   Hankeln, T ^a   Forst, T ^a   Pfutzner A ^a   Heerdt, S ^a   Walgenbach, S ^a   Lehnert, H ^c   Beyer, J ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GENETICS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MULTIPLE ENDOCRINE NEOPLASIA; ONCOGENE RET; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; ADOLESCENT; ADRENAL TUMOR; ANAMNESIS; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; FAMILY; GENETIC SCREENING; GENETICS; MEDULLARY CARCINOMA; MIDDLE AGED; MULTICENTER STUDY; PHEOCHROMOCYTOMA; PREDICTION AND FORECASTING; PRESCHOOL CHILD; PROTO ONCOGENE; SIPPLE SYNDROME; THYROID TUMOR;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; CARCINOMA, MEDULLARY; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FAMILY; FEMALE; GENETIC SCREENING; HUMANS; MALE; MEDICAL HISTORY TAKING; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PHEOCHROMOCYTOMA; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENES; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 0034695260     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1023904     Document Type: Article

References (40)

1. 1 Berndt, I., M. Reuter, B. Saller, K. Frank-Raue, P. Groth, M. Grussendorf, F. Raue, M.M. Ritter, W. Höppner. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J. Clin. Endocrinol. Metab. 83 (1998), 770-774.
2. 2 Biddinger, P. W., M. F. Brennan, P. P. Rosen: Symptomatic C-cell hyperplasia associated with chronic lymphocytic thyroiditis. Am. J. Surg. Pathol. 15 (1991), 599-604.
3. 3 Bolino, A., I. Schuffenecker, Y. Luo, M. Seri, M. Silengo, T. Tocco, G. Chabrier, C. Houdent, A. Murat, M. Schlumberger, J. Tourniaiere, G. M. Lenoir, G. Romeo: RET mutations in exons 13 and 14 of FMTC patients. Oncogene 10 (1995), 2415-2419.
4. 4 Conte-Devolx, B., I. Schuffenecker, P. Niccoli, B. Maes, A. Boneu, N. Barbot, J. B. Corcuff, A. Murat, J. F. Henry, E. Modigliani: Multiple endocrine neoplasia type 2: management of patients and subjects at risk. French Study Group on Calcitonin-Secreting Tumors (GETC). Horm. Res. 47 (1997), 221-226.
5. 5 Decker, R. A., M. L. Peacock, M. J. Borst, J. D. Sweet, N. W. Thompson: Progress in genetic screening of multiple endocrine neoplasia type 2A: is calcitonin testing obsolete? Surgery 118 (1995), 257-264.
6. 6 Donis-Keller, H., S. Dou, D. Chi, K. M. Carlson, K. Toshima, T. C. Lairmore, J. R. Howe, J F. Moley, P. Goodfellow, S. A. Wells Jr: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet. 2 (1993), 851-856.
7. 7 Dralle, H., G. F. Scheumann, C. Proye, F. Bacourt, A. Frilling, F. Limbert, G. Gheri, J. F. Henry, M. Berner, B. Niederle: The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study. J. Intern. Med. 238 (1995), 357-361.
8. 8 Dralle, H., O. Gimm, D. Simon, K. Frank-Raue, G. Gortz, B. Niederle, R. A. Wahl, B. Koch, S. Walgenbach, R. Hampel, M. M. Ritter, F. Speisberg, A. Heiss, R. Hinze, W. Höppner: Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J. Surg. 22 (1998), 744-750, discussion 750-751.
9. 9 Durbec, P., C. V. Marcos-Gutierrez, C. Kilkenny, M. Grigoriou, K. Wartoiwaara, P. Suvanto, D. Smith, B. Ponder, F. Costantini, M. Saarma, H. Saroila, V. Pachnis: GDNF signalling through the Ret receptor tyrosine kinase. Nature 381 (1996), 789-792.
10. 10 Eng, C., D. P. Smith, L. M. Mulligan, C. S. Healey, M. J. Zvelebil, T. J. Stonehouse, M. A. Ponder, C. E. Jackson, M. D. Waterfield, B. A. Ponder: A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 10 (1995), 509-513.
11. 11 Eng, C.: The RET Proto-Oncogene in Multiple Endocrine Neoplasia Type 2 and Hirschsprung's Disease. N. Engl. J. Med. 335 (1996), 943-951.
12. 12 Engelbach, M., S. Heerdt, R. Görges, T. Kunt, A. Pfützner, T. Forst, K. Diefenbach, S. Walgenbach, J. Beyer: Is there an ectopic secretion of monomeric calcitonin in the human being ? Langenbecks Arch. Surg. 383 (1998), 456-459.
13. 13 Frank-Raue, K., W. Höppner, A. Frilling, J. Kotzerke, H. Dralle, R. Haase, K. Mann, F. Seif, R. Kirchner, J. Rendl, H. F. Deckart, M. M. Ritter, R. Hampel, J. Klimpa, G. H. Scholz, F. Raue: Mutations of the ret Protooncogene in German Multiple Endocrine Neoplasia Families: Relation between Genotype and Phenotype. J. Clin. Endocrinol. Metab. 81 (1996), 1780-1783.
14. 14 Frank-Raue, K., W. Hoppner, H. Buhr, C. Herfarth, F. Raue: Results and follow-up in eleven MEN 2A gene carriers after prophylactic thyroidectomy. Exp. Clin. Endocrinol. Diabetes 105 Suppl. 4 (1997), 76-78.
15. 15 Frank-Raue, K., W. Höppner, H. Buhr, C. Herfarth, R. Ziegler, F. Raue: Mutationen des ret-Protoonkogens bei medullärem Schilddrüsenkarzinom. Dtsch. Med. Wochenschr. 122 (1997), 143-149.
16. 16 Gagel, R. F., A. H. Tashijian, T. Cummings, N. Papathanasopoulos, M. M. Kaplan, R. A. DeLellis, H. J. Wolfe, S. Reichlin: The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. N. Engl. J. Med. 318 (1988), 478-484.
17. 17 Gagel, R. F.: The abnormal pentagastrin test. Clinical Endocrinology 44(1996), 221-222.
18. 18 Gallegos-Martinez, J., M. F. Herrera, J. P. del-Rincon, R. Decker, A. Angeles-Angeles, O. Gonzalez J. A. Rull: A false-positive diagnosis of C-cell hyperplasia in a member of a family with multiple endocrine neoplasia type 2A and familial colonic polyposis. Surgery 123 (1998), 587-588.
19. 19 Gimm, O., J. Ukkat, H. Dralle: Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J. Surg. 22 (1998), 562-567, discussion 567-568.
20. 20 Grauer, A., F. Raue, R. Ziegler: Clinical usefulness of a new chemiluminescent two-site immunoassay for human calcitonin. Exp. Clin. Endocrinol. Diabetes 106 (1998), 353-359.
21. 21 Heshmati, H. M., H. Gharib, S. Khosla, H. S. Abu-Lebdeh, N. M. Lindor, S. N. Thibodeau: Genetic testing in medullary thyroid carcinoma syndromes: mutation types and clinical significance. Mayo Clin. Proc. 72 (1997), 430-436.
22. 22 Hofstra, R. M., R. M. Landsvater, I. Ceccherini, R. P. Stulp, T. Stelwagen, Y. Luo, B. Pasini, J. W. Hoppener, H. K. van Amstel, G. Romeo, C. J. M. Lips, C. H. C. M. Buys: A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367 (1994), 375-376.
23. 23 Kwok, J. B. J., E. Gardner, J. P. Warner, B. A. J. Ponder, L. M. Mulligan: Structural analysis of the human ret proto - oncogene using exon trapping. Oncogene 8 (1993), 1087-1091.
24. 24 Landsvater, R. M., A. G. Rombouts, G. J. te-Meerman, J. M. Schillhorn van Veen, M. J. Berends, R. A. Geerdink, A. Struyvenberg, C. H. Buys, C. J. Lips: The clinical implications of a positive calcitonin test for C-cell hyperplasia in genetically unaffected members of an MEN2A kindred. Am. J. Hum. Genet. 52 (1993), 335-342.
25. 25 Learoyd, D. L., D. J. Marsh, A. L. Richardson, S. M. Twigg, L. Delbridge, B. G. Robinson: Genetic testing for familial cancer. Consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia type 2. Arch. Surg. 132 (1997), 1022-1025.
26. 26 Lips, C. J. M., R. M. Landsvater, J. W. M. Höppener, R. A. Geerdink, G. Blijham, J. M. Jansen-Schillhorn van Veen, A.P.G. van Gils, M.J. de Wit, R. Zewald, M. J. H. Berends, F. A. Beemer, J. Brouwers-Smalbraak, R. P. M. Jansen, H. K. Ploos van Amstel, T. J. M. V. van Vroonhoven, T. M. Vroom: Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N. Engl. J. Med. 331 (1994), 828-835.
27. 27 Marsh, D., D. McDowall, V. Hyland, S. Andrew, M. Schnitzler, E. Gaskin, D. Nevell, T. Diamond, L. Delbridge, P. Clifton-Bligh, B. Robinson: The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN II a families. Clinical Endocrinology 44 (1996), 213-220.
28. 28 Mathew, C. G., K. S. Chin, D. F. Easton, K. Thorpe, C. Carter, G. I. Liou: A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 328 (1987), 527-528.
29. 29 Moley, J. F.: The molecular genetics of multiple endocrine neoplasia type 2A and related syndromes. Annu. Rev. Med. 48 (1997), 409-420.
30. 30 Mulligan, L. M., J. B. Kwok, C. S. Healey, M. J. Elsdon, C. Eng, E. Gardner, D. R. Love, S. E. Mole, J. K. Moore, L. Papi, M. A. Ponder, H. Telenius, A.Tunnacliffe, B. A. J. Ponder: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363 (1993), 458-460.
31. 31 Mulligan, L. M., D. H. Marsh, B. G. Robinson, I. Schuffenecker, J. Zedenius, C. J. M. Lips, R. F. Gagel, S. I. Takai, W. W. Noll, M. Fink, F. Raue, A. Lacroix, S. N. Thibodeau, A. Frilling, B. A. J. Ponder, C. Eng: Genotype - phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J. Intern. Med. 238 (1995), 343-346.
32. 32 Saad, M. F., N. G. Ordonez, R. K. Rashid, J. J. Guido, C. S. Hill Jr, R. C. Hickey, N. A. Samaan: Medullary carcinoma of the thyroid: A study of the clinical features and prognostic factors in 161 patients. Medicine 63 (1984), 319-342.
33. 33 Shirahama, S., K. Ogura, H. Takami, K. Ito, T. Tohsen, A. Miyauchi, Y. Nakamura: Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma. J. Hum. Genet 43 (1998), 101-106.
34. 34 Simpson, N. E., K. K. Kidd, F. J. Goodfellow, S. Myers, Jr. Kidd: Assignement of multiple endocrine neoplasia type 2A to chromosone 10 by linkage. Nature 328 (1987), 528-530.
35. 35 Takahashi, M., Y. Buma, T. Iwamoto, J. Inaguma, H. Ikeda, H. Hiai: Cloning and expression of the RET proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 3 (1988), 571-578.
36. 36 Tisell, L. E., G. Hansson, S. Jansson, H. Salander: Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 99 (1986), 60-66.
37. 37 Trupp, M., E. Arenas, M. Fainzilber, A. S Nilsson, B. Sieber, M. Grigoriou, C. Kilkenny, E. Salazar Grueso, V. Pachnis, U. Arumäe, H. Saroila, M. Saarma, C. Ibanez: Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 381 (1996), 785-789.
38. 38 Walgenbach, S., E. Sternheim, F. Bittinger, T. Junginger: Operative Therapie bei differenziertem Schilddrüsenkarzinom. Zentralbl. Chir 122 (1997), 252-258.
39. 39 Wells, S. A. Jr., D. D. Chi, K. Toshima, L. P. Dehner, C. M. Coffin, B. Dowton, J. L. Ivanovich, M. K. DeBenedetti, W. G. Dilley, J. F. Moley, J. A. Norton, H. Donis-Keller: Predictive DNA testing and prophylactic thyroidectomy in patients at risk für multiple endocrine neoplasia type 2A. Ann. Surg. 220 (1994), 237-250.
40. 40 Wells, S. A. Jr., M. A. Skinner: Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Exp. Clin. Endocrinol. Diabetes 106 (1998), 29-34.